RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
← Back to Research Library
Mechanism of Action
Tesamorelin is a stabilized GHRH(1-44) analogue with an N-terminal modification. FDA-approved as Egrifta for HIV-associated lipodystrophy, it specifically promotes visceral adipose tissue lipolysis through restored GH signaling while preserving subcutaneous fat.
Key Research Findings
- FDA-approved: Reduced visceral adipose tissue by 15-18% over 26 weeks
- 37% relative hepatic fat reduction vs placebo in NAFLD trial with fibrosis attenuation
Peer-Reviewed Studies (4)
Falutz J, Allas S, et al.
New England Journal of Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.2% vs 5.0% increase with placebo
Stanley TL, Feldpausch MN, et al.
JAMA (2014)
Tesamorelin reduced visceral adipose tissue by 9.9% and produced significant liver fat reductions
Stanley TL, Fourman LT, et al.
Lancet HIV (2019)
37% relative hepatic fat reduction with tesamorelin and attenuated fibrosis progression
Falutz J, Potvin D, et al.
Journal of Acquired Immune Deficiency Syndromes (2010)
Confirmatory Phase III showing ~18% visceral fat reduction
Research Disclaimer: The studies referenced above are from publicly available peer-reviewed literature. Pepta Labs products are sold strictly for research purposes. They are not intended for human consumption, therapeutic use, or as dietary supplements. All information is provided for educational and research reference only.